초록 ▼

Avermectin analogs are disclosed wherein the 6,6-spiroketal ring system has been reduced in size to a 6,5-spiroketal ring system by the deletion of the 25-position carbon atom and the 25-alkyl substituent and which has a 23-acyl cycloalkyl, phenyl or substituted hydroxymethyl substituent. This is ac

Avermectin analogs are disclosed wherein the 6,6-spiroketal ring system has been reduced in size to a 6,5-spiroketal ring system by the deletion of the 25-position carbon atom and the 25-alkyl substituent and which has a 23-acyl cycloalkyl, phenyl or substituted hydroxymethyl substituent. This is accomplished by opening the outer spiroketal ring with the elimination of ring carbon atoms 23, 24 and 25 and the alkyl substituent at the 25-position and incorporation a new component, reclosing the spiroketal to a 5-membered ring with a 23-acyl substituent and new substituents at the 24-position. The compounds are used as anti-parasitic insecticidal and anti-helmintic agents in humans and animals and compositions containing such compounds as the active ingredient thereof are also disclosed.

대표청구항 ▼

A compound having the following structural formula: [Figure] wherein R is [Figure] C3-C8 cycloalkyl or phenyl; R9 is C1-C8 alkyl, C2-C8-alkenyl, C1-C8-alkoxy, C3-C8 cycloalkyl or phenyl; R1 is hydrogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 alkoxy-C1-C10 alkyl or C1-C10 alkylthio-C1-C

A compound having the following structural formula: [Figure] wherein R is [Figure] C3-C8 cycloalkyl or phenyl; R9 is C1-C8 alkyl, C2-C8-alkenyl, C1-C8-alkoxy, C3-C8 cycloalkyl or phenyl; R1 is hydrogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 alkoxy-C1-C10 alkyl or C1-C10 alkylthio-C1-C10 alkyl group; a C3-C8 cycloalkyl or C5-C8 cycloalkenyl group, either of which may optionally be substituted by methylene or from 1 to 3 of C1-C4 alkyl groups or halo atoms; phenyl, phenoxy, C1-C10 alkyl phenyl, C2-C10 alkenyl phenyl, C2-C10 alkynyl phenyl, substituted C1-C10 alkyl wherein the substituents independently are 1 to 3 of C1-C5 alkyl, C3-C8 cycloalkyl or substituted C1-C10 alkyl wherein the substutuents are independently 1 to 3 of hydroxy, halogen, cyano, C1-C5 alkyl thio, C1-C5 alkyl sulfinyl, C1-C5 alkyl sulfonyl, amino, C1-C5 mono or dialkyl amino, C1-C5 alkanoyl amino or C1-C5 alkanoylthio; or a 3 to 6 membered oxygen or sulfur containing heterocylic ring which may be saturated, or fully or partly unsaturated and which may optionally be substituted independently by 1 to 3 of C1-C5 alkyl, halogen; R2 is hydroxy, C1-C10 alkoxy, C1-C10 alkanoyloxy, oxo or oxime; R3 is hydrogen, hydroxy, C1-C10 alkyloxy, C1-C8 alkanoyloxy, C1-C5 alkoxy-C1-C5-alkoxy, C1-C5 alkoxy-C1-C5-alkoxy-C1-C5-alkoxy, halogen, [Figure] [Figure] wherein R4 is attached to C-4″or C-4′by a single bond and is hydroxy, amino, N-C1-C8 alkylamino, N,N-C1-C8-dialkylamino, N-C1-C8 alkanoylamino, N-C1-C5 alkyl C1-C5 alkanoylamino, C1-C8 alkylthio, C1-C8 alkyl sulfinyl, C1-C8 alkyl sulfonyl or substituted C1-C8 alkyl thio, sulfinyl or sulfonyl where the substituents are from 1 to 5 of hydroxy, halogen, amino or mono or di-C1-C3 alkylamino; or R4 is attached to C-4″or C-4′by a double bond and is ketone, oxime, semicarbazono, N-C1-C8 alkylsemicarbazono, N,N-C1-C8 diloweralkylsemicarbazono, C1-C8 alkanoylhydrazono, benzoylhydrazono, or C1-C8 alkylbenzoyl-hydrazono; and each R5 is independently hydroxy or C1-C10 alkoxy; or R4 is [Figure] or R4 is [Figure] [Figure] R4 is －NH－CO－HR6R7, R6 and R7 and R8 are independently hydrogen or C1-C10 alkyl; or R4 is －NH－CN.